Stereochemistry | RACEMIC |
Molecular Formula | C17H17ClFN3O3.ClH |
Molecular Weight | 402.248 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC1CCN(C1)C2=C(Cl)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O
InChI
InChIKey=BMACYHMTJHBPOX-UHFFFAOYSA-N
InChI=1S/C17H17ClFN3O3.ClH/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9;/h5,7-9H,1-4,6,20H2,(H,24,25);1H
Clinafloxacin is a broad-spectrum fluoroquinolone antibiotic that was originally developed and subsequently abandoned in the late 1990s as a human health antibiotic for respiratory diseases. Clinafloxacin displays broad-spectrum antibacterial activity against Gram-positive, Gram-negative, and anaerobic pathogens by inhibiting the bacterial regulatory enzyme DNA gyrase (IC50 = 0.92 ug/ml) as well as topoisomerase IV (IC50 = 1.62 ug/ml).
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Patients were treated with clinafloxacin (200 mg iv q12h or, if known or suspected of being infected with more-resistant pathogens, 400 mg q12h).
Route of Administration:
Intravenous